Verrica Pharmaceuticals Inc (VRCA) Stock Price, Quote & News

Company Profile

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 453 3300

Website: www.verrica.com

Address:

44 West Gay Street, Suite 400, West Chester, United States

CEOBuysDisclosures Aug. 18 at 11:05 PM

$VRCA CEO purchased 25,000 shares at $5.03 for a total of $125,750. Rieger Jayson now owns 207,838 shares. https://ceo-buys.com

0 · Reply

DonCorleone77 Aug. 18 at 9:38 PM

$VRCA Verrica Pharmaceuticals CEO buys $125.8K in common stock In a regulatory filing, Verrica Pharmaceuticals disclosed that its CEO Jayson Rieger bought 25K shares of common stock on August 14th in a total transaction size of $125.8K.

0 · Reply

JFais Aug. 18 at 9:29 PM

$VRCA (NP) Former Black Sheep pick, CEO with $125.8K purchase 🧐

0 · Reply

Zephix Aug. 9 at 8:42 PM

$VRCA Phase 3 common-warts program advancing..⚕️

0 · Reply

BDE_Worldwide Aug. 6 at 10:51 PM

$VRCA been here a looooong time.. surprised to see PBM still shoveling money into this enterprise.. wonder what he sees..?

1 · Reply

BioGem Aug. 6 at 10:42 PM

$VRCA The same exact points I mentioned before, persist and worsen over time. Most importantly, adoption by doctors is too poor, and cash ran out, while losses are destroying the company. Now they are adding expensive debt.

1 · Reply

AlphaMatrix Aug. 6 at 10:31 PM

$VRCA units surged but revenue barely moved. Monetization gap is widening. Physicians adopting. Patients not paying.

0 · Reply

EarningsInsider Aug. 6 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-verrica-pharmaceuticals-inc-stock/ $VRCA Verrica Pharmaceuticals Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 6 at 8:44 PM

$VRCA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.62 down -3200.00% YoY • Reported revenue of $5.86M down -53.85% YoY

0 · Reply

11thestate Aug. 5 at 7:39 PM

Verrica Pharmaceuticals ($VRCA) finally agreed to settle with investors over claims it misled the market about FDA approval risks for VP-102. What happened? Investors alleged Verrica downplayed manufacturing problems at Sterling, a key contract manufacturer for VP-102, and repeatedly suggested FDA issues had been resolved. In May 2022, the company disclosed a third Complete Response Letter tied to Sterling, raising new concerns about the drug's approval timeline. Who qualifies? Investors who purchased $VRCA between 2021 and 2022. Apply here: https://11th.com/cases/verricapharmaceuticals-investor-settlement

0 · Reply

Verrica Pharmaceuticals CEO buys $125.8K in common stock

2026-08-06T21:31:11.000Z - 12 days ago

Verrica Pharmaceuticals reports Q2 EPS (62c), consensus (47c)

Aug 6, 2026, 4:30 PM EDT - 12 days ago

Verrica Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 12 days ago

Verrica Pharmaceuticals Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 12 days ago

Verrica Pharmaceuticals Quarterly report: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Jul 21, 2026, 8:00 AM EDT - 4 weeks ago

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Jun 22, 2026, 8:05 AM EDT - 2 months ago

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Jun 4, 2026, 11:05 AM EDT - 2 months ago

Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:05 AM EDT - 2 months ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

2026-05-26T10:19:56.000Z - 3 months ago

Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright

May 19, 2026, 1:30 PM EDT - 3 months ago

Verrica Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026, 8:00 AM EDT - 3 months ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

2026-05-12T21:57:53.000Z - 3 months ago

Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)

May 12, 2026, 4:30 PM EDT - 3 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Verrica Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Verrica Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 4:01 PM EDT - 3 months ago

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

May 5, 2026, 4:05 PM EDT - 3 months ago

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

SID

May 5, 2026, 8:00 AM EDT - 3 months ago

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Verrica Pharmaceuticals Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Verrica Pharmaceuticals Proxy statement: Proxy filing

Apr 15, 2026, 3:00 PM EDT - 4 months ago

Verrica Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 4:05 PM EDT - 4 months ago

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Verrica Pharmaceuticals Slides: Corporate presentation

Mar 11, 2026, 8:30 AM EDT - 5 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 11, 2026, 8:30 AM EDT - 5 months ago

Verrica Pharmaceuticals Annual report: Q4 2025

Mar 11, 2026, 8:30 AM EDT - 5 months ago

Verrica Pharmaceuticals Earnings release: Q4 2025

2026-03-11T12:06:44.000Z - 5 months ago

Verrica Pharmaceuticals reports Q4 adjusted EPS (51c), consensus (79c)

Mar 11, 2026, 8:00 AM EDT - 5 months ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 8:00 AM EST - 5 months ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

Mar 2, 2026, 10:30 AM EST - 6 months ago

Verrica Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 8:00 AM EST - 6 months ago

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

2026-02-12T13:11:17.000Z - 6 months ago

Verrica Pharmaceuticals appoints Chapman as Chief Commercial Officer

Feb 12, 2026, 8:00 AM EST - 6 months ago

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

2026-02-09T13:20:47.000Z - 6 months ago

Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan

Feb 9, 2026, 8:00 AM EST - 6 months ago

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

Jan 9, 2026, 7:00 AM EST - 7 months ago

Verrica Pharmaceuticals Slides: Investor presentation

2026-01-07T13:16:25.000Z - 8 months ago

Verrica announces first patient dosed in program evaluating YCANTH

Jan 7, 2026, 8:00 AM EST - 8 months ago

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

2025-12-18T02:10:17.000Z - 8 months ago

Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline

2025-12-15T21:25:42.000Z - 8 months ago

Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders

Dec 15, 2025, 7:00 AM EST - 8 months ago

Verrica Pharmaceuticals Registration statement: Registration Filing

2025-11-24T13:11:05.000Z - 9 months ago

Verrica Pharmaceuticals announces private placement financing of $50M

Nov 24, 2025, 8:00 AM EST - 9 months ago

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

Nov 17, 2025, 8:30 AM EST - 9 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 17, 2025, 8:30 AM EST - 9 months ago

Verrica Pharmaceuticals Earnings release: Q3 2025

Nov 17, 2025, 8:30 AM EST - 9 months ago

Verrica Pharmaceuticals Quarterly report: Q3 2025

2025-11-14T21:10:36.000Z - 9 months ago

Verrica Pharmaceuticals reports Q3 adjusted EPS 13c, consensus (84c)

Nov 14, 2025, 4:05 PM EST - 9 months ago

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

2025-11-10T13:15:34.000Z - 10 months ago

Verrica Pharmaceuticals presents new data on VP-315 from Phase 2 trial

Nov 10, 2025, 8:00 AM EST - 10 months ago

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

2025-11-05T11:46:01.000Z - 10 months ago

Verrica Pharmaceuticals initiated with a Buy at Lucid Capital

Oct 24, 2025, 11:00 AM EDT - 10 months ago

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

2025-10-20T20:45:12.000Z - 10 months ago

Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing

Oct 20, 2025, 4:05 PM EDT - 10 months ago

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

Oct 7, 2025, 4:05 PM EDT - 11 months ago

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

2025-09-19T12:05:32.000Z - 11 months ago

Verrica Pharmaceuticals development partner receives approval for YCANTH

Sep 19, 2025, 8:00 AM EDT - 11 months ago

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

Sep 8, 2025, 9:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

2025-07-09T11:15:25.000Z - 1 year ago

Verrica reports 13,434 YCANTH dispensed applicator units in Q2

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

2025-07-01T11:16:21.000Z - 1 year ago

Verrica announces amendment to collab, license agreement with Torri

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 13, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 7, 2025, 3:00 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 8, 2025, 1:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Annual report: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings release: Q4 2024

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Registration statement: Registration Filing

Mar 3, 2025, 2:30 PM EST - 1 year ago

Verrica Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

Feb 25, 2025, 4:05 PM EST - 1 year ago

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Dec 9, 2024, 4:15 PM EST - 1 year ago

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 6, 2024, 8:00 AM EST - 1 year ago

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Nov 21, 2024, 7:30 AM EST - 1 year ago

Verrica Announces Pricing of $42.0 Million Public Offering

Nov 20, 2024, 4:05 PM EST - 1 year ago

Verrica Announces Proposed Public Offering

Nov 4, 2024, 9:30 AM EST - 1 year ago

Verrica Pharmaceuticals Quarterly report: Q3 2024

Nov 4, 2024, 9:30 AM EST - 1 year ago

Verrica Pharmaceuticals Earnings release: Q3 2024

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

Oct 11, 2024, 5:21 PM EDT - 2 years ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Oct 2, 2024, 7:30 AM EDT - 2 years ago

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

Sep 27, 2024, 10:29 PM EDT - 2 years ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

CEOBuysDisclosures Aug. 18 at 11:05 PM

$VRCA CEO purchased 25,000 shares at $5.03 for a total of $125,750. Rieger Jayson now owns 207,838 shares. https://ceo-buys.com

0 · Reply

DonCorleone77 Aug. 18 at 9:38 PM

0 · Reply

JFais Aug. 18 at 9:29 PM

$VRCA (NP) Former Black Sheep pick, CEO with $125.8K purchase 🧐

0 · Reply

Zephix Aug. 9 at 8:42 PM

$VRCA Phase 3 common-warts program advancing..⚕️

0 · Reply

BDE_Worldwide Aug. 6 at 10:51 PM

$VRCA been here a looooong time.. surprised to see PBM still shoveling money into this enterprise.. wonder what he sees..?

1 · Reply

BioGem Aug. 6 at 10:42 PM

1 · Reply

AlphaMatrix Aug. 6 at 10:31 PM

$VRCA units surged but revenue barely moved. Monetization gap is widening. Physicians adopting. Patients not paying.

0 · Reply

EarningsInsider Aug. 6 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-verrica-pharmaceuticals-inc-stock/ $VRCA Verrica Pharmaceuticals Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 6 at 8:44 PM

$VRCA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.62 down -3200.00% YoY • Reported revenue of $5.86M down -53.85% YoY

0 · Reply

11thestate Aug. 5 at 7:39 PM

0 · Reply

Stock_Catcher Jul. 21 at 12:03 PM

$VRCA Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

0 · Reply

Bbboston Jul. 20 at 7:33 PM

$VRCA Yahoo showing Only 4950 shares traded today so far and it’s 3:30!!!

0 · Reply

arturogf Jun. 11 at 4:38 PM

My take on $VRCA https://www.tradingview.com/chart/VRCA/oIzCS3aM-Clear-accumulation-for-VRCA/?social_toast=true

0 · Reply

DARKP00L May. 26 at 11:27 AM

$VRCA 06:51 on May. 26 2026 HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12 #tradeideas

0 · Reply

Bbboston May. 23 at 2:12 PM

$VRCA Yes 315 could be a huge money maker, but if YCANTH shows to be effective for common warts, that could be huge as well.

0 · Reply

t_lamp3 May. 13 at 8:44 PM

$VRCA Everyone’s focused on YCANTH revenue… meanwhile the real lottery ticket is VP-315. A potential injectable alternative to cutting basal cell carcinomas off. Phase 2 showed: • 51% complete histologic clearance • 97% response rate • Minimal systemic exposure If Phase 3 hits, this isn’t just another derm company anymore. Feels like the market still thinks VRCA is a molluscum-only story. https://verrica.com/press_release/verrica-pharmaceuticals-presents-new-data-on-vp-315-from-its-phase-2-clinical-trial-in-basal-cell-carcinoma-at-the-40th-society-for-immunotherapy-of-cancer-annual-meeting/

0 · Reply

flatrock100 May. 13 at 5:29 PM

$VRCA strong rev growth

1 · Reply

MarketBeat May. 13 at 3:09 AM

https://marketbeat.com/a/8651239/ $VRCA Verrica Pharmaceuticals Q1 Earnings Call Highlights

0 · Reply

EarningsInsider May. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-verrica-pharmaceuticals-inc-stock/ $VRCA Verrica Pharmaceuticals Earnings Transcript

0 · Reply

BioGem May. 12 at 9:29 PM

$VRCA I have mentioned their dismal performance for the past 6 months, and not sure why investors still bought it, all while they diluted by double the number of shares not too long ago. -Adoption of the product in the USA is too weak and slow, despite a big expansion in their sales team. -Their losses are deepening. -Cash burn is too heavy and unsustainable. -Cash is already critically low. -Add several millions in pre-funded warrant already vested. -I expect another round of dilution imminently.

0 · Reply

Merlintrader May. 12 at 8:21 PM

$VRCA Verrica Pharmaceuticals (Nasdaq: $VRCA): Q1 2026 earnings show stronger YCANTH demand, lower debt burden and a still-tight cash clock https://www.merlintrader.com/verrica-pharmaceuticals-deepdive-april2026/

0 · Reply

StocktwitsEarnings May. 12 at 8:12 PM

$VRCA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.45 up 55.00% YoY • Reported revenue of $5.02M up 46.06% YoY

0 · Reply

Market Cap	84.01M
Revenue (ttm)	35.58M
Net Income (ttm)	-17.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-50.28%
Debt to Equity Ratio	0.00

Volume	107,007
Avg Vol	43,400
Day's Range	N/A - N/A
Shares Out	17.18M
Stochastic %K	0%
Beta	1.49
Analysts	Strong Sell
Price Target	$14.80